On February 13, 2026, Maple Private Equity Fund announced the completion of its angel round investment in EasyMed Aura (Shenzhen) Medical Co.,Ltd. ("EasyMed"). This investment is aimed at supporting EasyMed 's R&D innovation in the field of interventional medical devices and promoting the independent development of high-end domestic interventional devices.

Founded on March 18, 2025, EasyMed is a high-tech enterprise specializing in the R&D of interventional medical devices. The company's primary business covers three major areas: cardiovascular, neurovascular, and oncological interventions, with a commitment to enhancing the clinical accessibility and technological competitiveness of high-end domestic interventional devices through independent R&D. EasyMed 's core team is composed of multiple experts with extensive experience in the field of medical device R&D, and its technological solutions have already received preliminary clinical validation.

As the investor in this round, Maple Private Equity Fund has expressed high recognition for EasyMed 's technological strength and market prospects. The fund's representative stated: "EasyMed possesses enormous innovative potential in the interventional device sector. We look forward to accelerating its product R&D and market promotion through this investment, bringing more breakthroughs to the domestic healthcare industry."